News About: Pharm. Industry
Intensified polarization in R&D investment among listed pharms
Although it is estimated there were more than 6 listed pharmaceutical companies investing more than KRW 100 billion into R&D in a year, there were also a number of pharmaceutical products spending less than 1% of thei...
Celltrion records KRW 196.6 billion sales and KRW 89.4 billion operating profits
Celltrion announced on the 11th that it recorded KRW 196.578 billion sales in the 1st quarter of 2017, increased by 81.2% compared to the same quarter of the last year.
Its operating profits were KRW 89.394 billion i...
Daewoong, “There has been no Nabota counterfeit distributed in Korea so far’Daewoong Pharmaceutical(CEO Jong-Wook Lee) announced the company was working on distribution of ‘Nabota’ counterfeits on the 12th and revealed an intermediate result that there ...
|
Alvogen Korea’s KRW 4.49 billion sales in 1st quarter, recording losses for the quarterAlvogen Korea announced on the 15th it recorded KRW 44.91 billion sales in the 1st quarter of 2017, decreased by 1.4% compared to the same quarter of the last year.
The company...
|
Merz Korea signs business agreement of ‘Contractubex’ with C&C HealthcareFollow by the business agreement for ‘Pantogar’ last March, Merz Korea is newly launching an OTC drug business by selecting a new partner for ‘Contractubex,’ a scar treatment.
...
|
Listed pharmas did well with operating activities in 1st quarter, but got weakened in profitability
Although listed pharmaceutical companies have recorded decent performances with business activities in the 1st quarter, their profitability was analyzed to be weakened for various reasons including non-operating losse...
Ildong’s chronic hepatitis B treatment ‘Besivo Tab’ become 28th Korean new drugIldong Pharmaceutical(CEO Woong-Sup Yoon) acquired approval of ‘Besivo Tab(generic name: besifovir dipivoxil maleat),’ a new chronic hepatitis B treatment developed by on its ow...
|
JW Pharmaceutical acquires license of ‘emicizumab,’ innovative hemophilia A treatmentJW Pharmaceutical acquired a license of a hemophilia A treatment improved in administration convenience in Korea.
JW Pharmaceutical(CEO Sung-Kwon Han, Young-Seop Shin) announce...
|
Celltrion reveals Remsima clinical trial result on Crohn’s disease at DDW symposium
At the U.S. Digestive Disease Week(DDW) symposium at Chicago from the 6th to 9th of May, Celltrion revealed a result of the Remsima clinical trial(CT-P12 2.4 CD) on active Crohn’s disease patients and a result of the ...
KHIDI’s ‘Tailored Consulting Program’ for pharmaceutical and biotechnology fields
The Korea Health Industry Development Institute(KHIDI) announced on the 10th it will support consulting expenses for medium and small pharmaceutical companies on R&D planning, licensing, approval and marketing.
Appli...
